Glycosmedia

Diabetes News Service

Diabetes News

Tag: SGLT2 inhibitors

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients

Use of SGLT2i improved cardiac function in diabetic patients, regardless of the presence of HF. The improvements were more prominent in HF patients, especially in those with HFrEF. These improvements in cardiac function would contribute to the clinical benefit of SGLT2i (Cardiovascular Diabetology)

Comparative effectiveness of dapagliflozin vs DPP ‐4 inhibitors on a composite endpoint of HbA1c , body weight, and blood pressure reduction in the real world

T2D patients initiating the SGLT2i dapagliflozin had a greater probability of attaining a composite endpoint of clinically relevant reductions in HbA1c, body weight and SBP, compared to similar patients initiating a DPP‐4i in the same period and healthcare setting (Diabetes/Metabolism Research and Reviews)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

In this large, population-based study, the use of ACE inhibitors and ARBs was more frequent among patients with Covid-19 than among controls because of their higher prevalence of cardiovascular disease. However, there was no evidence that ACE inhibitors or ARBs affected the risk of COVID-19 (NEJM)

Evolving evidence of diabetic ketoacidosis in patients taking sodium glucose cotransporter 2 inhibitors

SGLT2i are an excellent class of drug in the physician’s toolkit for managing type 2 diabetes. However, both clinicians and patients must be aware of the potential for DKA and the need for increased monitoring, both clinically and biochemically, when potential precipitating factors are present. In acutely unwell patients, these medications should be withheld to reduce the risk of DKA (Journal of Clinical Endocrinology & Metabolism)

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney

Here, we present meta-analysis of the four key CVOTs indicating a major role of renal function in determining the extent of MACE prevention, with the benefit increasing in more severe kidney disease, that is, a high-risk condition where effectiveness of the traditional approach with statins is reduced (Cardiovascular Diabetology)

Sodium–glucose co‐transporter‐2 inhibitor cardiovascular outcome trials and generalizability to English primary care

There was variation in proportions of the primary care type 2 diabetes population fulfilling inclusion criteria of SGLT‐2i CVOTs. The more stringent the inclusion criteria, the lower the proportion identified in a primary care setting. Prescription rates for SGLT‐2is were low in this national database, and there were demographic disparities in prescribing (Diabetic Medicine)

A metabolomics based molecular pathway analysis for how the SGLT2‐inhibitor dapagliflozin may slow kidney function decline in patients with diabetes

The observed molecular pathways targeted by dapagliflozin and associated with DKD suggest that modifying molecular processes related to energy metabolism, mitochondrial function, and endothelial function may contribute to its renal protective effect (Diabetes, Obesity and Metabolism)

SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action

There is compelling evidence that sodium–glucose cotransporter 2 (SGLT2) inhibitors exert cardioprotective and renoprotective effects that are far greater than expected based on their effects on glycemia or glycosuria (Diabetes Care)

Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis

Long‐acting GLP‐1RAs showed superiority in reducing HbA1c levels, body weight and waist circumference. SGLT‐2is showed reductions in blood pressure levels. This review provide essential evidence to guide treatment recommendations in the management of type 2 diabetes (Diabetes, Obesity and Metabolism)

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients

SGLT2 inhibitors had glucose-lowering effects comparable to those of DPP4 inhibitors but more favorable pleiotropic effects on body weight, ALT and eGFR changes, potentially improving type 2 diabetes patients’ cardio-metabolic disease risks (Cardiovascular Diabetology)

SGLT‐2 Inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk

While confirmatory of the exploratory data from CVOTs, CREDENCE provides the first robust data on the effects of canagliflozin on patient relevant renal endpoints. Extrapolation to a conclusion of a SGLT2 inhibitor class effect cannot be made until additional renal trials with other SGLT2 inhibitors are reported (Diabetes, Obesity and Metabolism)

Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis

Sodium‐glucose cotransporter 2 inhibitors protect against cardiovascular disease and death in diverse subsets of patients with type 2 diabetes mellitus regardless of cardiovascular disease history (Journal of the American Heart Association)

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices

Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com